FAKTOR-OPTIONSSCHEIN - GILEAD SCIENCES | Delayed Deutsche Boerse AG 07:08:35 2024-07-12 am EDT | ||
| 4.11 EUR | -1.91% |
|
| Current month | -6.26% | ||
| 1 month | -19.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 4.11 | -1.91% |
| 24-07-11 | 4.19 | -3.90% |
| 24-07-10 | 4.36 | -2.24% |
| 24-07-09 | 4.46 | -1.11% |
| 24-07-08 | 4.51 | -2.59% |
Delayed Quote Deutsche Boerse AG
Last update July 12, 2024 at 07:08 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Société Générale
|
| WKN | SB0QMV |
| ISIN | DE000SB0QMV3 |
| Date issued | 2020-06-04 |
| Strike | 73.21 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 8.98 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.58 € |
|---|---|
| Lowest since issue | 2.93 € |
| Spread | 0.03 € |
| Spread % | 0.72% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
69.97
USD
Average target price
83.08
USD
Spread / Average Target
+18.74%
- Stock Market
- Certificates
- Certificat